Autonomix Medical, Inc. (AMIX) stock
Close on Nov 12, 2026Market cap $1.32MP/E –Yield –
Autonomix Medical, Inc. reported revenue of $0 for the twelve months to Sep 30, 2026. Free cash flow was -$12.29M. At the latest close the market valued the company at $1.32M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.32M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.19
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$11.78M
- EPS, diluted
- -$8.12
- Free cash flow
- -$12.29M
- Book value per share
- $5.56
- Diluted shares
- 1M
Trading
- Previous close
- $1.48
- Open
- $1.44
- Day's range
- $1.30 – $1.44
- Volume
- 502,861
- Average volume (20 days)
- 3,764,438
- Beta (5 years)
- 1.60
- 52-week range
- $1.42 – $32.55
- RSI (14 days)
- 26.0
- Volatility (1 year)
- 456.8%
- Relative volume
- 0.33×
- WACC
- 12.9%
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | AMIX | S&P 500 | Difference | AMIX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -56.3% | -2.7% | −53.6 pts | ||
| 3 months | -82.0% | -1.7% | −80.3 pts | ||
| Year to date | -88.3% | +11.9% | −100.2 pts | ||
| 1 year | -92.4% | +12.0% | −104.4 pts |
Five years at a glance
Fiscal years 2022 to 2026 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Autonomix Medical filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- Update
- Update
- News
About Autonomix Medical
Surgical & Medical Instruments & Apparatus
Autonomix Medical is a development-stage medical device enterprise focused on advancing diagnostic and therapeutic technologies for nervous system disorders. The company develops a catheter-based platform that combines high-sensitivity neural signal detection with targeted radiofrequency ablation, utilizing a "sense, treat, verify" approach to improve procedural precision. Its primary offerings comprise a proprietary microchip-enabled sensing catheter, an RF ablation catheter, a dedicated RF generator, and visualization software. Designed to navigate transvascular pathways, these systems target peripheral nerve fibers initially to manage pain associated with pancreatic cancer. The technology is tailored for interventional radiologists and cardiologists operating in hospital catheter laboratories, with potential future applications covering additional visceral pain conditions, hypertension, and other nerve-related disorders.
Company profile, executives and historyAutonomix Medical stock: common questions
What is Autonomix Medical's stock price?
AMIX closed at $1.35 on Nov 12, 2026, down 8.45% on the day. Over the past 52 weeks it traded between $1.42 and $32.55.
What is Autonomix Medical's market cap?
Autonomix Medical was worth $1.32M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is AMIX's P/E ratio?
Autonomix Medical lost money over the twelve months to Sep 30, 2026 (diluted EPS -$8.12), so it has no meaningful P/E ratio.
How much revenue does Autonomix Medical make?
Autonomix Medical reported revenue of $0 for the twelve months to Sep 30, 2026.
Does Autonomix Medical pay a dividend?
No. Autonomix Medical has not paid a cash dividend over the last twelve months.
How has AMIX stock performed over the past year?
Including dividends, AMIX returned -92.4% over the past year, against +12.0% for the S&P 500.
How many AMIX shares are sold short?
0M shares were sold short at the latest FINRA report, 6.20% of the float, or 1.0 days of average trading volume.
Who are Autonomix Medical's competitors?
Companies most similar to Autonomix Medical by business, industry and size include NMTC, CVRX, OBIO, ATRC, DRTS.
See a number that looks wrong?